Recombinant interferon-alpha, but not interferon-gamma is effective therapie for essential thrombocythemia
Authors:
- 1 January 1990
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 60 (1) , 37-40
Abstract
Recombinant interferon-gamma with a starting dose of 0.5 mg 3×/week subcutaneously, was administered to 6 patients with essential thrombocythemia (median platelet count 1172×109/1, range 602–1564). Four of the patients had received alkylating agents previously. Hematological remission, defined as a decrease in platelet counts to ≤ 350×109/l, was observed in none of these patients. Subsequently 4 of these 6 patients, supplemented by 2 others were treated with interferonalpha2c at a dose of 5×106 U daily subcutaneously. Five patients showed hematological remission. In case of hematological remission the interferonalpha dosis was reduced to 5× an thereafter to 3× weekly 5×106 U. During an observation period ranging from 12–41 weeks platelet counts remained normal in all patients. Side-effects were mild and consisted of fever, myalgias, malaise and itching occurring mainly during the first month of treatment. No dose adaptation was required. The patients treated previously with interferon-gamma experienced the side effects from this drug less tolerably than those from the alpha-compound. These observations suggest that recombinant interferonalpha may be an effective drug in treating essential thrombocythemia resulting in a sustained response.Keywords
This publication has 27 references indexed in Scilit:
- LONG-TERM INTERFERON THERAPY FOR THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASESThe Lancet, 1989
- In vivo and in vitro inhibitory effect of α‐interferon on megakaryocyte colony growth in essential thrombocythaemiaBritish Journal of Haematology, 1989
- TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA WITH INTERFERON ALPHA-2bThe Lancet, 1989
- TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA BY ALPHA 2a INTERFERONThe Lancet, 1988
- ALPHA-INTERFERON THERAPY FOR ESSENTIAL THROMBOCYTHAEMIAThe Lancet, 1988
- Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustardAmerican Journal of Hematology, 1988
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986
- Primary thrombocythaemia treated with busulphanBritish Journal of Haematology, 1986
- Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosisScandinavian Journal of Haematology, 1985
- Therapeutic Effect of Human Recombinant Interferon-Alpha-2C in Essential ThrombocythaemiaOncology, 1985